Finance

In the wake of Eli Lilly’s impressive second-quarter earnings report, the company’s stock price surged by a significant 8%. This surge was largely attributed to the company’s revenue and earnings blowing past expectations, as well as the increase in its full-year revenue outlook by $3 billion. The sales of the blockbuster diabetes drug Mounjaro and
0 Comments